Medical Weight Loss (Semaglutide & Tirzepatide)

Medically supervised weight loss program at AlphaMan Men's Health Clinic in Sherman Oaks, Los Angeles, using GLP-1 receptor agonist medications including semaglutide and tirzepatide (GIP/GLP-1 dual agonist). Supervised by Dr. Allen Lawrence (M.D., M.A., Ph.D.) with ongoing monitoring and nutrition guidance. Clinical programs project 10–20% body weight reduction. MIC lipotropic plus B12 injections and phentermine also available as adjunct options.

AlphaMan Men's Health Clinic's medical weight loss program is designed for men seeking a physician-supervised approach to achieving and sustaining significant body weight reduction, particularly for those with obesity-related metabolic risks, low testosterone (which is associated bidirectionally with adiposity), or weight management challenges unresponsive to lifestyle interventions alone. The program's primary pharmacological tools are GLP-1 receptor agonist medications: semaglutide (a GLP-1 analogue administered as a weekly subcutaneous injection, commercially available as Ozempic/Wegovy) and tirzepatide (a dual GIP/GLP-1 receptor agonist administered weekly, commercially available as Mounjaro/Zepbound). Both medications reduce appetite and caloric intake through central nervous system effects on satiety centers, slow gastric emptying to prolong satiety after meals, and improve insulin sensitivity and glucose metabolism. Clinical trial data for both agents demonstrates 10–20% body weight loss over 52–72 week treatment periods in the appropriate patient population, representing the most effective pharmacological weight loss tools currently available. Tirzepatide's dual GIP/GLP-1 mechanism produces additional metabolic benefits on lipid profiles, hepatic fat, and glycemic control. Under Dr. Lawrence's supervision, the program begins with a comprehensive metabolic and hormonal blood panel to baseline metabolic health, insulin resistance markers, thyroid function, testosterone (adiposity suppresses testosterone through aromatization and SHBG reduction), and cardiovascular risk. The GLP-1 program is paired with nutrition and lifestyle guidance, with patients monitored at regular intervals via lab work and clinical assessment. Phentermine — a sympathomimetic appetite suppressant — is available as an adjunct or alternative for appropriate candidates. MIC lipotropic injections (methionine, inositol, choline) combined with B12 are used as a complement to GLP-1 therapy to support fat metabolism and energy levels during caloric restriction. The program also addresses the testosterone-adiposity interaction: restoring testosterone toward optimal range can independently improve body composition and metabolic rate, creating a synergistic effect when TRT and medical weight loss are managed together.